BofA Securities resumed coverage on Merck with a new price target
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities resumed coverage of Merck with a rating of Buy and set a new price target of $121.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $110.00 | Buy → Hold | Truist |
| 12/20/2024 | $136.00 → $105.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/10/2024 | $121.00 | Buy | BofA Securities |
| 12/4/2024 | $130.00 | Hold → Buy | HSBC Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/11/2024 | Buy → Neutral | Daiwa Securities | |
| 10/17/2024 | $115.00 | Mkt Perform | Bernstein |
| 3/11/2024 | $104.00 | Hold → Sell | Societe Generale |
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression will be stopped early. The decision to stop the HYPERION study prior to its scheduled completion was based on the positive results from the interim
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the second quarter of 2025. Payment will be made on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. The Board also authorized an additional $10 billion of treasury stock purchases with no time limit for completion. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, in combination with chemotherapy (KEYTRUDA plus LENVIMA-based regimen), for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma. At an interim analysis, the KEYTRUDA plus LENVIMA-based regimen demonstrated a statistically significant improvement in prog
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
8-K - Merck & Co., Inc. (0000310158) (Filer)
10-Q - Merck & Co., Inc. (0000310158) (Filer)
8-K - Merck & Co., Inc. (0000310158) (Filer)
Truist downgraded Merck from Buy to Hold and set a new price target of $110.00
BMO Capital Markets downgraded Merck from Outperform to Market Perform and set a new price target of $105.00 from $136.00 previously
BofA Securities resumed coverage of Merck with a rating of Buy and set a new price target of $121.00
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022. Among the world's most admired global business leaders, Mr. Frazier is the executive chairman and former CEO of Merck (NYSE:MRK), chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil Corporation (NYSE:XOM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005316/en/Kenneth C. Frazi
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the second quarter of 2025. Payment will be made on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. The Board also authorized an additional $10 billion of treasury stock purchases with no time limit for completion. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 4. During the call, company executives will provide an overview of Merck's performance for the fourth quarter and outlook for 2025. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialin
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens